White Paper | Platinum Market Dynamics and Their Impact on Cancer Treatment Costs
Platinum-based chemotherapy drugs such as cisplatin, carboplatin, and oxaliplatin remain essential to cancer treatment worldwide. Because these APIs contain significant amounts of platinum, their cost structure is directly influenced by fluctuations in platinum prices.
After years of relative stability, the unprecedented platinum rally of 2025 created new challenges across the healthcare value chain. API costs rose sharply, tender-based procurement systems struggled to adapt, and supply shortages emerged in several markets.
In our latest white
paper, Platinum Market Dynamics and Their Impact on Cancer Treatment
Costs, we explore:
- The
key drivers behind the 2025 platinum rally
- The
consequences for pharmaceutical pricing and supply
- Challenges
for pharmaceutical manufacturers and healthcare systems
- Strategies to help mitigate risk and protect access to
critical therapies
